• Company
• The cobas SARS-CoV-2 & Influenza A/B Test was approved
• by May 10, 2021 05:56am

• Product
• Will Kypris become dominant in multiple myeloma markets?
• by Whang, byung-woo May 10, 2021 05:56am

• Company
• The trend to advertise vaccines is diversity and young men
• by May 7, 2021 06:02am

• Company
• Cherry Huang to succeed Jenny Zheng as head of Janssen Korea
• by Eo, Yun-Ho May 7, 2021 06:01am

• Company
• “Evenity is effective in patients at very-high-risk of OP"
• by May 7, 2021 06:01am

• Product
• Pharmacists & employees in their 20s receive Pfizer vaccine
• by May 7, 2021 06:01am

• Policy
• 40 new drugs licensed last year
• by Lee, Tak-Sun May 7, 2021 06:01am

• Policy
• The National Assembly is trying to enact GMP legislation
• by Lee, Jeong-Hwan May 6, 2021 06:07am

• Company
• Why SK and GC's deal for Xarelto exclusivity right misfired
• by Kim, Jin-Gu May 6, 2021 06:07am

• Company
• Moderna’s next steps in Korea…vaccine production scenarios
• by Kim, Jin-Gu May 6, 2021 06:07am